Starpharma Holdings Ltd (ASX: SPL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Starpharma Holdings Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$40.97 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
418.11 million
Earnings per share
-0.020
Dividend per share
N/A
Year To Date Return
-41.18%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Starpharma Holdings Ltd (ASX: SPL)
Latest News
Share Market News
Top broker makes FY19 picks
⏸️ Investing
Why these 4 ASX shares are ending the week in the red
⏸️ Investing
The Starpharma Holdings Limited (ASX:SPL) share price surges on global expansion deal
⏸️ Investing
Why these 4 ASX shares are jumping higher today
⏸️ Investing
This analyst says Mortgage Choice Limited and Starpharma Holdings Ltd are a sell
⏸️ Investing
Why these shares are taking off
⏸️ Investing
Why the Starpharma Holdings Limited share price rocketed higher today
⏸️ Investing
Why the Starpharma Holdings Limited share price rocketed 10% higher today
⏸️ Investing
Why these 4 ASX shares have jumped higher today
⏸️ Investing
Here's why these 4 ASX shares got slammed today
⏸️ Investing
Movers & shakers on the ASX today
⏸️ Investing
S&P/ASX 200 DIVES as bank selloff continues
Frequently Asked Questions
-
No, Starpharma does not pay dividends at this time.
-
Starpharma listed on the ASX on 28 September 2000.
SPL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Starpharma Holdings Ltd
Starpharma Holdings Ltd (ASX: SPL) is an Australian biotechnology company involved in the development of dendrimer products for pharmaceutical, life science, and other applications.
Dendrimers are synthetically manufactured, nanoscale molecules, particularly useful to the pharmaceutical industry for their unique properties as carriers of other molecular structures.
Starpharma describes itself as a world leader in the field. The company is developing programs for drug delivery applications, the treatment of respiratory viruses, and its VivaGel product.
VivaGel can be used for the management and prevention of bacterial vaginosis and as a coating for condoms. The company's VIRALEZE product is an antiviral nasal spray approved for use in many countries, including Europe and the UK.
SPL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Dec 2024 | $0.10 | $0.00 | 0.00% | 210,851 | $0.11 | $0.11 | $0.10 |
| 19 Dec 2024 | $0.10 | $0.00 | 0.00% | 606,389 | $0.11 | $0.11 | $0.10 |
| 18 Dec 2024 | $0.10 | $0.00 | 0.00% | 1,086,559 | $0.10 | $0.10 | $0.10 |
| 17 Dec 2024 | $0.10 | $0.00 | 0.00% | 272,200 | $0.11 | $0.11 | $0.10 |
| 16 Dec 2024 | $0.11 | $-0.01 | -9.09% | 122,351 | $0.11 | $0.12 | $0.11 |
| 13 Dec 2024 | $0.11 | $-0.01 | -8.70% | 4,243 | $0.12 | $0.12 | $0.11 |
| 12 Dec 2024 | $0.12 | $0.00 | 0.00% | 50,284 | $0.12 | $0.12 | $0.12 |
| 11 Dec 2024 | $0.12 | $0.00 | 0.00% | 259,648 | $0.12 | $0.12 | $0.12 |
| 10 Dec 2024 | $0.12 | $0.00 | 0.00% | 30,427 | $0.12 | $0.12 | $0.12 |
| 09 Dec 2024 | $0.12 | $0.01 | 9.09% | 262,121 | $0.11 | $0.12 | $0.11 |
| 06 Dec 2024 | $0.11 | $0.01 | 9.52% | 668,393 | $0.11 | $0.11 | $0.11 |
| 05 Dec 2024 | $0.11 | $-0.01 | -9.09% | 105,074 | $0.11 | $0.11 | $0.11 |
| 04 Dec 2024 | $0.11 | $-0.01 | -8.70% | 276,783 | $0.11 | $0.11 | $0.11 |
| 03 Dec 2024 | $0.12 | $0.00 | 0.00% | 138,359 | $0.12 | $0.12 | $0.11 |
| 02 Dec 2024 | $0.12 | $0.00 | 0.00% | 754,666 | $0.12 | $0.12 | $0.11 |
| 29 Nov 2024 | $0.12 | $0.01 | 9.52% | 293,806 | $0.11 | $0.12 | $0.11 |
| 28 Nov 2024 | $0.11 | $0.00 | 0.00% | 6,316 | $0.11 | $0.11 | $0.11 |
| 27 Nov 2024 | $0.11 | $-0.01 | -8.70% | 132,218 | $0.12 | $0.12 | $0.11 |
| 26 Nov 2024 | $0.12 | $0.00 | 0.00% | 304,398 | $0.12 | $0.12 | $0.12 |
| 25 Nov 2024 | $0.12 | $0.00 | 0.00% | 509,432 | $0.11 | $0.12 | $0.11 |
| 22 Nov 2024 | $0.12 | $0.00 | 0.00% | 86,930 | $0.11 | $0.12 | $0.11 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 11 Dec 2024 | Cheryl Maley | Issued | 5,202,703 | $598,310 |
Issue of securities. 7,401,386 Performance Rights, As per announcement on 12-12-2024
|
| 05 Nov 2024 | Robert Thomas | Buy | 300,000 | $28,000 |
On-market trade.
|
| 23 Oct 2024 | Robert Thomas | Buy | 200,000 | $18,500 |
On-market trade.
|
| 23 Oct 2024 | Robert Thomas | Buy | 300,000 | $27,750 |
On-market trade.
|
| 13 Sep 2024 | Russell Basser | Buy | 200,000 | $18,600 |
On-market trade.
|
| 02 Sep 2024 | David McIntyre | Buy | 405,886 | $3,879 |
On-market trade. As per announcement on 02-09-2024
|
| 02 Sep 2024 | Robert Thomas | Buy | 350,000 | $3,246 |
On-market trade.
|
| 28 Jun 2024 | Jeff Davies | Buy | 879,687 | $79,699 |
On-market trade.
|
| 26 Jun 2024 | Robert Thomas | Buy | 200,000 | $17,800 |
On-market trade.
|
| 25 Jun 2024 | Lynda Cheng | Buy | 110,555 | $9,950 |
On-market trade.
|
| 20 Jun 2024 | Robert Thomas | Buy | 250,000 | $22,679 |
On-market trade.
|
| 30 May 2024 | Cheryl Maley | Buy | 125,000 | $14,065 |
On-market trade.
|
| 29 May 2024 | Robert Thomas | Buy | 150,000 | $17,750 |
On-market trade.
|
| 15 Apr 2024 | Robert Thomas | Buy | 100,000 | $13,000 |
On-market trade.
|
| 12 Apr 2024 | Russell Basser | Buy | 71,428 | $10,002 |
On-market trade.
|
| 10 Apr 2024 | Robert Thomas | Buy | 250,000 | $43,424 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Robert Bain Thomas | Non-Executive DirectorNon-Executive Chairman | Dec 2013 |
Mr Thomas has background in financial services and capital markets and is a non-executive director of several Australian listed companies. He was previously a Partner of Potter Partners (now UBS), where he was also Head of Research. He is a member of Risk Committee.
|
| Ms Cheryl Ann Maley | Chief Executive OfficerManaging Director | Jan 2024 |
Ms Maley has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie. Her previous roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie/Abbott, Servier Laboratories, and Wyeth Pharmaceuticals.
|
| Mr David McIntyre | Non-Executive Director | Mar 2020 |
Mr McIntyre has more than 20 years of executive experience including 18 years in the life sciences sector, having held various C-suite level roles at Tessa Therapeutics, Inc., AVITA Therapeutics, Inc., HeartWare International, Inc., and Braeburn, Inc. He is the Chair of Risk Committee.
|
| Ms Lynda Cheng | Non-Executive Director | Aug 2021 |
Ms Cheng has over 25 years of experience as a finance executive, including substantial international experience and several non-executive directorships, Ms Cheng's experience covers the majority of key areas described in Starpharma's Board skills matrix. In particular, she has expertise in accounting/corporate finance, audit and risk; M&A/capital markets; strategy and risk management; governance; as well as business development. Ms Cheng has had involvement in the commercialisation of new innovations during her tenure at South East Water and also while working with disruptive technology companies in Silicon Valley. She is a member of Risk Committee.
|
| Dr Jeff Davies | Non-Executive Director | Apr 2022 |
Dr Davies has over 35 years of experience within the biopharmaceutical industry, Dr Davies is an accomplished executive skilled in R&D, product development and commercialisation strategy, business development, manufacturing and clinical and regulatory affairs. Dr Davies has leadership skills and experience in commercialising scientific research for healthcare products.
|
| Dr Russell Basser | Non-Executive Director | Feb 2023 |
Dr Basser has over 20 years of executive experience in the biotechnology industry and 10 years as a practicing clinical oncologist, Dr Basser has leadership skills and experience in healthcare/scientific research; pharmaceutical product development; international executive experience and skills in regulation/public policy; commercialisation of innovation; business development; governance; strategy; and risk management.
|
| Mr Justin Cahill | Chief Financial OfficerCompany Secretary | Apr 2023 |
-
|
| Justin Cahill | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 81,247,474 | 19.70% |
| JP Morgan Nominees Australia PTY Limited | 31,174,308 | 7.56% |
| Citicorp Nominees Pty Limited | 15,203,959 | 3.69% |
| BNP Paribas Noms Pty Ltd | 14,494,331 | 3.51% |
| Bell Potter Nominees Ltd <Bb Nominees A/C> | 9,000,000 | 2.18% |
| Ingot Capital Investments Pty Ltd | 8,705,000 | 2.11% |
| T & N Argyrides Investments P/L <T & N Argyrides Pension A/C> | 5,060,000 | 1.23% |
| BNP Paribas Nominees Pty Ltd <Clearstream> | 4,866,370 | 1.18% |
| Mr Kingsley Bryan Bartholomew | 4,612,025 | 1.12% |
| Lavya Pty Ltd <Lavya Family A/C> | 4,344,628 | 1.05% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 4,267,008 | 1.03% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 4,141,107 | 1.00% |
| Mr Peter Murray Jackson | 3,921,959 | 0.95% |
| E Equities Pty Ltd | 3,700,000 | 0.90% |
| All States Finance Pty Limited | 3,500,000 | 0.85% |
| Applecross Secretarial Services Pty Ltd <L Gorr Family A/C> | 3,361,550 | 0.82% |
| Ms Jacinth Fairley | 3,252,386 | 0.79% |
| Charles & Cornelia Goode Foundation Pty Ltd <CCG Foundation A/C> | 3,200,000 | 0.78% |
| Mr Thomas Argyrou | 3,000,000 | 0.73% |
| BNP Paribas Nominees Pty Ltd <IB AU Noms Retail Client> | 2,739,822 | 0.66% |
